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Abstract
Streptococcal toxic shock syndrome (STSS) caused by Streptococcus pyogenes is a clinical condition with a high mortality
rate despite modern intensive care. A key feature of STSS is excessive plasma leakage leading to hypovolemic hypotension,
disturbed microcirculation and multiorgan failure. Previous work has identified a virulence mechanism in STSS where M1
protein of S. pyogenes forms complexes with fibrinogen that activate neutrophils to release heparin-binding protein (HBP),
an inducer of vascular leakage. Here, we report a marked inter-individual difference in the response to M1 protein–induced
HBP release, a difference found to be related to IgG antibodies directed against the central region of the M1 protein. To
elicit massive HBP release, such antibodies need to be part of the M1 protein–fibrinogen complexes. The data add a novel
aspect to bacterial pathogenesis where antibodies contribute to the severity of disease by promoting a pathologic
inflammatory response.
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Introduction
Streptococcus pyogenes is a major human bacterial pathogen that
causes a wide range of infections from common and mostly
uncomplicated cases of pharyngitis and impetigo, to severe
invasive infections [1]. Since the 1980s an unexplained increased
incidence of these severe infections has been reported world-wide,
and it is estimated that invasive S. pyogenes infections, streptococcal
toxic shock syndrome (STSS) and necrotizing fasciitis, are
responsible for more than 150 000 deaths annually [2,3]. These
conditions have attracted considerable attention and concern, also
in the public, due to their acute and dramatic nature. Despite
modern intensive care and prompt and adequate antibiotic
therapy, they are associated with high mortality rates [4–6].
A potent inflammatory response leading to shock and organ
failure is typical of STSS. Previous work has shown that secreted S.
pyogenes exotoxins play an important role in STSS by inducing this
response. Thus, STSS patients have a propensity to produce high
levels of inflammatory cytokines in response to these superantigens
[7]. There is also a correlation between the severity of S. pyogenes
infection and HLA class II allelic variation [8], suggesting that the
regulation of superantigen-triggered cytokine response contributes
to S. pyogenes pathogenicity. Moreover, binding of plasminogen to
the bacterium and the subsequent activation to plasmin represents
a virulence mechanism that has been proposed to promote the
transition from a localized infection into a severe invasive disease
[9]. Streptolysin-O-induced platelet/neutrophil aggregation has
also been suggested to contribute to the vascular dysfunction in
severe S. pyogenes infection [10].
A key symptom in STSS is a massive vascular leakage (these
patients often require 10–20 liters of intravenous fluid per day)
leading to hypovolemic hypotension and multiorgan failure. A
molecular mechanism contributing to the vascular leakage in
STSS has been identified [11]. M protein, a classical virulence
determinant of S. pyogenes (for references, see review [12]), is
released from the surface of S. pyogenes, forms complexes with
fibrinogen that activate neutrophils to secrete Heparin-Binding
Protein, HBP (also known as azurocidin or CAP37), a powerful
inducer of increased vascular permeability [13]. The finding that
M protein binds fibrinogen was first reported by Kantor et al [14],
and the binding was subsequently mapped to the NH2-terminal
half of the protein but excluding the most distal hypervariable
region [15]. The proinflammatory effect of M1 protein-fibrinogen
complexes was further underlined by a recent and elegant
investigation, showing that a mutated form of M1 protein with
lower affinity for fibrinogen, lost its capacity to induce HBP release
and vascular leakage [16]. In the present work, a marked inter-
individual difference was recorded for the M protein-induced HBP
release in the blood of healthy individuals. This difference was
explained by the presence of specific IgG antibodies against M1
protein, giving rise to protein complexes containing M1 protein,
fibrinogen and IgG. Such complexes induce a massive release of
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and IgGFc receptors (via IgG bound to M protein in the
complexes exposing their Fc regions). The finding that IgG
antibodies against a bacterial antigen participate in the induction
of a severe and pathologic inflammatory response, represents a
novel concept in bacterial virulence.
Results
Individual variation in the M1 protein-induced release of
HBP in human blood is due to IgG antibodies
As mentioned, previous work has shown that M1 protein when
added to human blood, forms complexes with fibrinogen which
activate neutrophils to release HBP [11].The starting point for this
study was the observation that there is a marked individual
variation in the response to M1 protein. As shown in Fig. 1A, the
blood of some individuals responds with massive HBP release,
whereas others are non-responders (defined as a response of less
than 10% release of the total amount of HBP). As previously
reported [11], maximum HBP release in responder blood was
obtained at an M1 protein concentration of 1 mg/ml in blood
diluted 1:10. The recombinant M1 protein used in these
experiments does not contain LPS at a concentration that
influences the HBP release [11].
The antibody titers against M1 protein were determined in
serum samples from 19 responders and non-responders (Table 1).
Unexpectedly, the individuals with powerful responses also had
high anti-M1 antibody titers. When serum from a responder was
added to the blood of a non-responder together with M1 protein,
the serum induced HBP release. However, serum from a non-
responder did not (Fig. 1B). The IgG antibodies in the responder
serum were removed by protein G-Sepharose absorption, and this
IgG-depleted serum could no longer induce HBP release when
added to non-responder blood (Fig. 1B). The role of IgG was
further investigated by the use of enzymes that have IgG as their
only substrate. IdeS, also called Mac-1 [17], is a cysteine
proteinase secreted by S. pyogenes which is highly specific for IgG
antibodies [18]. The enzyme cleaves IgG in the hinge region to
generate one F(ab’)2 fragment and the two heavy chain
components of the Fc fragment. EndoS is an endoglycosidase,
also from S. pyogenes, that specifically removes the glycan from the
Fc region of IgG [19]. Responder serum was pre-treated with
either IdeS or EndoS, and then separately added (together with
M1) to non-responder blood. These serum samples lost their
capacity to induce HBP release in non-responder blood (Fig. 1B).
Finally, IgG was purified from responder and non-responder
serum. Only IgG from responder serum could, when added to
non-responder blood, induce HBP-release in the presence of M1
protein, and following pre-treatment with IdeS, IgG lost its HBP-
releasing activity (Fig. 1C). Taken together the results demonstrate
that IgG antibodies are involved in the activation of neutrophils
leading to HBP release. IgG F(ab’)2 fragments generated by IdeS
cleavage and EndoS treated IgG devoid of its glycan, still
recognize and bind their antigen. However, the Fc region is
cleaved off by IdeS [18] and removal of the glycan by EndoS
results in lower affinity for the Fc receptor [20]. This suggests that
the IgG antibodies in responder serum inducing HBP release
require an intact Fc region to activate the neutrophils, presumably
by interacting with IgGFc receptors.
M1 protein and anti-M1 IgG antibodies induce HBP
release in human blood
The observation that IgG antibodies are required to induce a
powerful HBP release, raised questions about the specificity of
these antibodies. M1 protein, schematically depicted in Fig. 2A,
appeared as a possible candidate antigen, and surface plasmon
resonance technology was used to test this hypothesis. In these
experiments, M1 protein was initially flushed over a surface coated
with fibrinogen (Fig. 2B). The affinity between M1 protein and
fibrinogen is high, 1.1610
10 M
21 [21], which is evident from the
rapid binding of M1 protein in the left part of Fig. 2B. The
interaction between fibrinogen and M1 protein was allowed to
reach equilibrium, followed by separate injections of IgG purified
from the sera of one responder and two non-responders. In
contrast to the IgG preparations from the non-responders,
responder serum contains IgG antibodies that bind to the M1
protein associated with fibrinogen (Fig. 2B, right part). These
results indicate that IgG antibodies inducing HBP release in
responder sera are directed against the M1 protein.
A classical observation in streptococcal research is that S.
pyogenes bacteria survive and grow in human whole blood, provided
there are no type specific anti-M protein antibodies directed
against the hyper-variable NH2-terminal region of the M protein
expressed by the strain in question [22]. This region in the very
NH2-terminal region of M proteins comprises 50–100 amino acid
residues and shows a high degree of variation among strains of
different M types. There are more than one hundred M types [23],
but within a given type the sequence is conserved. To find out
whether antibodies against this NH2-terminal region are impor-
tant for the induction of HBP release, the growth of M1 bacteria
was investigated in the blood of seven different individuals, four
responders and three non-responders. The results of Fig. 3A show
that the bacteria grew well in the blood from the non-responder
and three of the responders, whereas growth was completely
inhibited in the blood of one responder. The lack of correlation
between the presence of bactericidal antibodies directed against
the NH2-terminal region of M1 protein and HBP release, indicates
that IgG antibodies against other regions of the M1 protein are
required for HBP release. The AS fragment covers the 191 NH2-
terminal amino acids of the mature protein M1 protein containing
the hypervariable A domain , the fibrinogen-binding B domains
and the S domain (Fig. 2A). Adding the AS peptide to blood from
a non-responder together with serum from a responder, elicited
HBP release (Fig. 3B). Compared to intact M1 protein the dose
response is different for the AS fragment. This has previously been
reported [11] and is due to the fact that different molar
concentrations of M1 protein and the AS fragment are required
Author Summary
Streptococcus pyogenes, also known as group A strepto-
coccus, is a common bacterial pathogen mostly causing
rather harmless infections such as pharyngitis (‘‘strep
throat’’) and impetigo (a superficial skin infection).
However, sometimes these bacteria give rise to severe
invasive infections, and one of the most feared conditions
in infection medicine is streptococcal toxic shock syn-
drome (STSS). In STSS, the mortality remains high despite
modern intensive care and the fact that S. pyogenes is
susceptible to penicillin. Why some people develop this
serious condition and others not is still not fully
understood. The common dogma is that antibodies
against a pathogenic microorganism are protective, but
in this work we show that certain antibodies actually
increase the risk for a more severe disease. This
information suggests that these antibodies could be used
as therapeutic targets, and the results may also facilitate
the identification of individuals prone to developing STSS.
Pro-Inflammatory IgG Antibodies
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SC3 fragment (Fig. 2A) does not contain the fibrinogen-binding B
domains or the hypervariable region (A), but spans the S domain
and the COOH-terminal region of the mature protein. This
peptide did not induce HBP release in an identical experiment,
suggesting that the interaction with fibrinogen is required.
However, when added at a molar excess together with M1 protein
to the blood of a non-responder supplemented with responder
serum, HBP release was inhibited (Fig. 3C). This indicates that
IgG antibodies promoting HBP release are absorbed by binding to
the SC3 fragment. Thus, since the only domain shared by the AS
and the SC3 fragments is the S domain and the SC3 fragment
inhibits the response, we conclude that the IgG antibodies
necessary for a massive HBP response bind to this domain (this
is also supported by the electron micrograph in Figure 3D). In
order to further pin-point the interaction, a synthetic peptide
covering the S domain was produced and tested for its capacity to
inhibit the response. This peptide had no inhibitory activity. Given
that short peptides often do not fold properly this was not an
unexpected result. The response to two other M proteins, M3 and
M5 protein, was also investigated in blood from M1 responders.
These proteins were tested under the same conditions as the M1
protein, but failed to elicit HBP release (data not shown). Finally,
IgG antibodies isolated from responder and non-responder serum
were separately incubated with purified M1 protein, and the
resulting protein complexes were analyzed by negative staining
electron microscopy (Fig. 3D). Inspection of large fields revealed
that compared to IgG from non-responders, responder IgG
generated much more complexes (data not shown). In these
complexes, the antibodies predominantly bound to epitopes in the
central region of the M1 protein (Fig. 3D). Taken together, the
experiments described in Fig. 3A–D suggest that the IgG
Figure 1. M protein-induced release of HBP shows inter-individual variation which is dependent on IgG antibodies. (A) Buffer or
various amounts of M1 protein was incubated with whole blood (diluted 1:10) from seven healthy individuals. The release of HBP was measured and
expressed as percentage of maximum (total lysis of blood with Triton-X). Data from at least three separate experiments are shown and expressed as
the mean6SD. (B) Whole blood (diluted 1:10) from an individual not responding with HBP release to the addition M1 protein, was used. M1 protein
(dark grey bars) or buffer (light grey bars), alone or together with plasma or serum samples from a responding or a non-responding individual, was
incubated with the blood. Serum from the responder was also depleted from IgG by protein G absorption, pre-treated with IgG-cleaving proteinase
IdeS or with the endoglycosidase EndoS to remove the glycan from IgG, prior to the incubation. Data are the median6interquartile range from at
least four different experiments. The HBP release elicited by serum from non-responders and pre-treated sera were compared against serum from the
responder using the Mann-Whitney U test and the result is shown as p values uncorrected for multiple comparisons. (C) Whole blood (diluted 1:10)
from an individual not responding with HBP release to M1 protein, was used. M1 protein (dark grey bars) or buffer (light grey bars), alone or together
with responder serum or purified IgG from a responding or a non-responding individual, was added the blood. Where indicated IgG from the
responder was pre-treated with IdeS. Data are the median6interquartile range from at least four different experiments. The HBP release elicited by
responder IgG was compared with the response elicited by non-responder IgG and by responder IgG pre-treated with IdeS using the Mann-Whitney
U test showing the crude p-values before Bonferroni correction.
doi:10.1371/journal.ppat.1000149.g001
Pro-Inflammatory IgG Antibodies
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against epitopes within or close to the central S domain of the M1
protein.
Protein complexes containing M1 protein, anti-M1 IgG
antibodies, and fibrinogen activate neutrophils to release
HBP
In a series of experiments, summarized in Fig. 4, it was
demonstrated that a powerful release of HBP by purified
neutrophils is generated only in the presence of M1 protein,
responder serum, and fibrinogen. The results suggest that protein
complexes comprised of M1 protein, IgG antibodies against M1
protein, and fibrinogen, are required, and that ordinary antigen-
antibody immune complexes are not sufficient to induce HBP-
release. To challenge this hypothesis, purified M1 protein was
added to responder and non-responder plasma. The precipitates
formed were analyzed by SDS-PAGE and Western blotting
(Fig. 5A). Precipitates from responder plasma contained all three
proteins, whereas IgG was missing in precipitates formed by
fibrinogen and M1 protein in non-responder plasma. M1 protein
also binds albumin [24], which explains the band of 65–70 kDa
seen in both precipitates. To investigate if the precipitates
contained complement proteins, Western blotting was performed
with anti-C3 antibodies. No significant bands could be detected in
any of the precipitates (data not shown). When added to whole
blood from a non-responding individual, pre-formed M1 protein
precipitates generated in responder plasma, induced HBP release
(Fig. 5B). As shown in Fig. 5B, this activity is abolished when the
precipitates are treated with IdeS or EndoS, enzymes which
specifically act on the Fc region of IgG. Moreover, non-responder
serum does not elicit HBP release. Finally, M1 protein was added
to responder or non-responder blood to induce the formation of
protein aggregates [11], which were subsequently analyzed by
scanning electron microscopy (Fig. 6). The protein aggregates
formed in responder blood contained neutrophils/monocytes,
whereas such cells were absent in aggregates of non-responder
blood. The HBP release was also measured in these blood samples
incubated with M1 protein, and elevated HBP levels were only
recorded in responder blood (data not shown). The results
described in this paragraph and in Figures 4–6, show that protein
complexes containing M1 protein, fibrinogen, and anti-M1
protein IgG antibodies, are required for a massive HBP release.
HBP release, Fcc receptors, and the role of platelets
To investigate the significance of Fcc receptor binding for HBP
release, inhibition experiments were performed with antibodies
against the various Fc receptors present on neutrophils (for
references see reviews [25,26,27]). Responder blood was pre-
incubated with anti-FccRI, anti-FccRII, anti-FccRIII, or isotype
control antibodies for 20 minutes, followed by the addition of M1
protein. Significant blocking of HBP release was obtained only
with the antibodies against FccRII (Fig. 7).
It was previously demonstrated that M1 protein forms
complexes with fibrinogen and IgG that activate platelets [28],
and we therefore investigated whether activated platelets through
interactions with neutrophils contribute to the release of HBP. The
results suggest that the activation of neutrophils resulting in HBP
release is independent of platelets. Thus, neutrophils purified from
platelets retained their full HBP-releasing activity when stimulated
by M1 protein in the presence of responder plasma (data not
shown).
Responder serum aggravates M1 protein-induced lung
lesions in mice
Intravenous (i.v.) injection of M1 protein induces lung lesions in
mice characterized by hemorrhage, fibrin deposits, and alveolar
swelling [11]. To address the question whether responder
Table 1. HBP release is related to anti-M1 titers.
Donor HBP release (% of maximum) Anti-M1 titer (ELISA-index)
1 14
2 19
3 11
4 14
5 23
6 31 0
7 33 9
8 41 3
9 52 0
10 65 9
11 84 0
12 86 0
13 97 9
14 15 65
15 17 44
16 18 129
17 18 75
18 34 174
19 34 96
doi:10.1371/journal.ppat.1000149.t001
Figure 2. Surface plasmon resonance spectroscopy detects
high affinity IgG antibodies against M1 protein in responder
serum. (A) Schematic depiction of mature M1 protein without the
signal peptide showing the AS and SC3 fragments. Fibrinogen binding
is mediated by the B domains, and the protein is associated with the
bacterial cell wall through the COOH-terminal D region. Numbers refer
to amino acid residue positions. (B) M1 protein was flushed over
BIAcore chips coated with fibrinogen. The dissociation phase of this
interaction was followed by the injection of purified IgG preparations
from one responder and two non-responders, and the binding is
expressed in resonance units (RU).
doi:10.1371/journal.ppat.1000149.g002
Pro-Inflammatory IgG Antibodies
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i.p. with responder serum, non-responder serum, or PBS, followed
by i.v. injection of M1 protein (15 mg/animal) or PBS 20 hours
later. After another 4 hours the animals were sacrificed and the
lungs were removed and analyzed by scanning electron micros-
copy. As previously reported, lesions with hemorrhage, fibrin
deposits, and alveolar swelling were found in all mice injected with
M1 protein, but they were more severe and wide-spread in the
lungs of mice that received responder-serum (Fig. 8). To avoid a
possible effect of LPS, the M1 protein preparation used in these
experiments was purified from S. pyogenes. Since mice injected with
only M1 protein also exhibit lung lesions, the blood of these
animals were screened by ELISA for anti-M1-antibodies. No such
antibodies were detected (data not shown). The results suggest that
the combination of responder serum and M1 protein causes more
severe lung lesions in mice than M1 protein alone.
Complexes of M1 protein, IgG and fibrinogen are formed
in a patient with necrotizing fasciitis and streptococcal
toxic shock syndrome (STSS)
We have previously identified complexes of fibrinogen and M1
protein in the affected tissue of a patient with necrotizing fasciitis
and STSS caused by an M1 isolate of S. pyogenes [11]. Here we
extend these studies to also include assessment of IgG antibodies in
the tissue. By use of protein L, a bacterial protein which binds
human immunoglobulins with high and specific affinity [29],
complexes of fibrinogen, M1 protein and IgG were visualized at
the epi-center of the tissue infection (Fig. 9). There were also areas
with only M1 protein, fibrinogen or IgG, verifying the specificity of
the stainings (Figure 9D). Some of the M1 protein was associated
with the streptococcal surface, but most of the protein was found in
the tissue not associated with the bacteria and in complexes with
fibrinogen (Fig. 9). IgG detected by protein L was found dispersed
within the tissue as well as in the M1 protein-fibrinogen
complexes. The data show the in vivo presence of M1-fibrinogen-
IgG complexes in the tissue of a patient with necrotizing fasciitis
and STSS.
Discussion
The outcome of a bacterial infection depends on the molecular
interactions between the bacterium and the human host. S. pyogenes
has developed a multitude of strategies to evade human defenses,
and it interferes with and manipulates the immune, complement,
coagulation and contact systems, whereby inflammatory reactions
Figure 3. Mapping of the antigenic region(s) in M1 protein responsible for HBP release. (A) Bacteria were added to whole blood from
seven donors; three non-responders and four responders. After three hours of incubation, blood was plated out and the number of colony forming
units was determined. In addition, the amount of HBP was determined in the blood from the seven donors. The multiplication factors and the HBP
values represent the mean6SD of at least three different experiments. (B) Whole blood (diluted 1:10) from an individual not responding with HBP
release to M1 protein, was used. Buffer or different concentrations of M1 protein or fragment AS of M1, was incubated with the blood together with
serum from a responder. Data are the median6interquartile range from at least four different experiments. (C) Whole blood (diluted 1:10) from an
individual not responding with HBP release to M1 protein was used. M1 protein was added to the blood (1 mg/ml corresponding to 20 nM)
supplemented with responder serum, together with 1, 10 or 100 times molar excess of fragment SC3 of M1. Data are the median6interquartile range
from at least four different experiments. (D) Negative staining and electron microscopy of M1 protein (arrows) incubated with IgG antibodies (arrow
heads) purified from the serum of a responder or a non-responder. Scale bar: 50 nm.
doi:10.1371/journal.ppat.1000149.g003
Pro-Inflammatory IgG Antibodies
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references see reviews [1,30]). The vast majority of individuals that
are colonized by S. pyogenes are asymptomatic carriers, but when
symptoms occur pronounced inflammation is typical for S. pyogenes
infections, also in local infections such as pharyngitis, pharyngo-
tonsillitis, and impetigo. However, STSS represents an invasive
disease where a systemic and extreme inflammation leads to
hypovolemic hypotension, disturbed microcirculation and multi-
organ failure. It is one of the most serious and feared conditions in
infection medicine.
STSS was originally described in the 1980s [31,32], and since
then there has been a worldwide increase in the incidence of the
disease [2]. A massive vascular leakage is a hallmark of STSS,
which explains the extreme loss of intravascular fluid and the rapid
course of the disease. Neutrophil activation is fundamental for the
induction of vascular leakage [33], and HBP is solely responsible
this effect [13]. The significance of HBP for vascular leakage in
severe infectious diseases is emphasized by work in our laboratory
showing that elevated plasma levels of HBP is an early indicator of
circulatory failure in sepsis (Linder et al., submitted for publica-
tion). M protein is a major surface protein of S. pyogenes [12], but
substantial amounts of M1 protein (0.4–0.6 mg/L growth
medium) is also shedded from the bacterial surface [21], suggesting
that high local concentrations of M1 protein can be reached at the
site of infection. The demonstration that soluble M1 protein forms
complexes with fibrinogen that activate neutrophils to unload their
HBP content, provided one explanation for how S. pyogenes induces
vascular leakage [11]. There are more than a hundred different M
serotypes [23], but strains of the M1 and M3 serotypes are
responsible for approximately fifty percent of the STSS cases [34].
From a patho-physiological point of view, it is therefore
noteworthy that the M1 and M3 proteins both contain multiple
fibrinogen-binding B domains (see Fig 2A), making it possible for
these proteins to generate neutrophil-activating complexes in
plasma environment.
When injected i.v. into mice, M1 protein/fibrinogen complexes
induce vascular leakage and lung lesions [11,16]. S. pyogenes is
regarded as an exclusive human pathogen and in this study we
could not identify any pre-existing antibodies against M1 protein
in mice, showing that such antibodies are not necessary to cause
these lung lesions. Whether the injection of M1 protein i.v. in
corresponding amounts into a human non-responder would result
in vascular leakage, is of course impossible to test. The fact that
M1 itself gives rise to lung lesions in our mouse model, complicates
experiments aimed at investigating the pathogenic role of anti-M1
antibodies. However, the fact that our most experienced electron
microscopist blindly could identify the most severely affected lungs
as those from mice treated with responder serum, supports that
such antibodies aggravate the disease. This assumption is also
supported by the observation that among 19 tested individuals,
Figure 5. M1 protein forms HBP-releasing precipitates with
fibrinogen and IgG in responder plasma. (A) Purified M1 protein
was added (10 mg/ml) to the plasma of a responder or a non-responder
(diluted 1:10). After incubation, the resulting precipitates were spun
down and the supernatants were saved. Precipitates were washed,
boiled in sample buffer and subjected to SDS-PAGE (lanes 1 and 4). The
supernatants (see above) were run in lanes 2 and 5, human plasma
diluted 1:500 was run in lanes 3 and 6, M1 protein (1.2 mg) in lane 7,
human polyclonal IgG (2 mg) in lane 8, and human fibrinogen (2.6 mg) in
lane 9. One gel was stained with Commassie Blue (STAIN), whereas an
identical gel was blotted onto an Imobilon filter and probed with goat
antibodies against human IgG (BLOT). (B) Whole blood diluted 1:10
from a non-responder was used. Buffer or M1 protein (1 mg/ml) was
added. M1 protein was pre-incubated with responder plasma and the
complexes formed were also tested. Such complexes were also
digested with IdeS or EndoS and subsequently added to the blood.
The release of HBP was measured and the data shown represent the
median6interquartile range from six separate experiments. The HBP
release from blood supplemented with complexes was compared to
the IdeS- or the EndoS- treated complexes using the Mann-Whitney U
test, and the result is shown as p values uncorrected for multiple
comparisons.
doi:10.1371/journal.ppat.1000149.g005
Figure 4. Fibrinogen is required for M1 protein-induced HBP
release by purified neutrophils. Fibrinogen (150 mg), M1 protein
(0.5 mg), or fibrinogen (150 mg) plus M1 protein (0.5 mg) were dissolved
in 0.45 ml PBS, followed by the addition of 50 ml responder (filled bars)
or non-responder serum (open bars). Neutrophils (2610
5 cells) were
added and after incubation for 30 min at 37uC, cells were spun down
and the amount of HBP was determined in the supernatants. The figure
shows the mean6SD of three separate experiments. The data obtained
with responder serum were compared using one way analysis of
variance, and the results showed a statistically significant difference
(p,0.001). The results obtained with M1 protein+fibrinogen were
compared with the HBP release generated by buffer, fibrinogen or M1
protein alone, using the Bonferroni corrected t-test. The corresponding
p-values are indicated.
doi:10.1371/journal.ppat.1000149.g004
Pro-Inflammatory IgG Antibodies
PLoS Pathogens | www.plospathogens.org 6 September 2008 | Volume 4 | Issue 9 | e1000149only those with significant anti-M1 IgG antibodies were HBP
responders.
Several previous investigations have demonstrated that large
antigen-antibody complexes generated in vitro are capable of
activating neutrophils[35,36,37]. In this study we find that a
massive release of HBP requires not only complexes of M1 protein
and anti-M1 IgG antibodies; they must also comprise fibrinogen.
M1/fibrinogen complexes activate neutrophils through multiple
interactions between fibrinogen molecules in the complexes and b2
integrins at the neutrophil surface, and this activation is blocked by
a b2 integrin antagonist [11]. A major conclusion of this work is
that the presence of anti-M1 IgG antibodies in the M1/fibrinogen
complexes results in the activation of FccII receptors, the
dominant activating receptors of neutrophils [25]. This dual
receptor activation is necessary for a powerful HBP release, an
observation that supports recent findings that co-stimulation of
neutrophil receptors has a synergistic effect on neutrophil
activation [38]. This is also supported by the finding that the
M3 and M5 proteins, which both bind fibrinogen but lack a region
homologous to the S domain, fail to induce HBP release in M1-
responders.
The initial observation that stimulated the current investigation,
was the finding that M1 protein, when added to the blood of
healthy donors, gave rise to an HBP release that showed a
significant inter-individual variation. A central question in
infection medicine is why some individuals colonized by a
pathogen show no symptoms, whereas other may develop severe
disease. As discussed above, this is a highly relevant question
concerning the pathogenesis of S. pyogenes, where the bacterium is
isolated from asymptomatic carriers as well as from patients with a
wide range of clinical manifestations, including life-threatening
STSS. Previous work in the field has helped to clarify this enigma
by demonstrating that STSS patients respond to S. pyogenes
exotoxins with high levels of pro-inflammatory cytokines [7], and
that this response is correlated with certain MHC class II
haplotypes [8]. The present work provides an additional
explanation to the inter-individual disease susceptibility, by
showing that also the humoral immune status contributes to the
inflammatory response in STSS.
In viral infections such as Dengue fever, re-infection induces a
more severe disease due to preformed IgG antibodies binding to
the virus particles. These antibodies expose their Fc regions and
activate FccR-expressing cells, referred to as antibody-dependant
enhancement (ADE) of infection [39], which results in a pro-
Figure 6. M1 protein-fibrinogen-IgG complexes bind to neutrophils/monocytes in responder blood. Buffer (A and C) or M1 protein
(1 mg/ml) (B and D) was incubated with whole blood (diluted 1:10) from a responder (A and B) and a non-responder (C and D). Red blood cells were
lysed and the samples were subjected to scanning electron microscopy. Arrows indicate neutrophils/monocytes. Scale bar: 20 mm.
doi:10.1371/journal.ppat.1000149.g006
Figure 7. Antibodies against FccRII inhibit HBP release. Whole
blood (diluted 1:10) was incubated with antibodies against different
FccRs, isotype control antibodies, or buffer alone, for 20 minutes at
37uC. M1 protein was added and the HBP release was measured. Data
are expressed as percentage of release without any antibodies added,
and are the mean6SD from three different individuals, each done in
duplicate. The different treatment groups were compared using
ANOVA, and when found significantly different the treatment groups
were compared against the control group using Dunnett’s 2 sided test.
doi:10.1371/journal.ppat.1000149.g007
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previously not been shown to contribute to the pathogenesis of
bacterial infections, and fibrinogen has not been ascribed a role in
the pathogenesis of Dengue fever. However, an early investigation
in a chicken model of S. aureus synovitis showed that chickens
treated with sera from chickens immunized with S. aureus,
developed a more severe disease [40]. The molecular background
for this was not explained.
The results of this study indicate that individuals with IgG
antibodies against the central region of the M1 protein, are more
prone to develop vascular leakage and severe disease. It is
therefore of interest that patients with fatal STSS and bacteremia
caused by S. pyogenes strains of the M1 serotype, were reported to
have low antibody titers against M1 protein [41]. The serum
samples from these patients were taken after the onset of the
disease, and the present results indicate that the low titers are due
to absorption of anti-M1 IgG antibodies in the M1-fibrinogen-IgG
complexes. To challenge this hypothesis, it would be most
interesting to analyze a collection of serum samples from
individuals prior to the on-set of the disease, and we are currently
trying to trace historical serum samples from STSS patients. As
anticipated, this has turned out to be very difficult and we have so
far failed to identify such samples.
Large intra-venous doses of pooled polyclonal IgG (IVIG) were
reported to have beneficial effects in patients with STSS [42,43]
and in an animal model of STSS [44]. Several molecular
mechanisms behind the action of IVIG have been suggested;
blocking of Fc receptors, modulation of Fc receptor expression,
cytokine responses and immune cell functions, neutralization of
superantigens, opsonising IgG antibodies, etc (reviewed in [45]).
IVIG is pooled from thousands of individuals and IVIG
preparations contain various anti-M protein IgG antibodies [46].
Antibodies against the type-specific NH2-terminal region of M
proteins promote killing of S. pyogenes in human blood, which
should be a beneficial effect. However, the data of this study show
that IgG antibodies binding predominantly to the central region of
the M1 protein, have the potential capacity to induce a deleterious
HBP release. Thus, the removal of these antibodies may enhance
the therapeutic effect of IVIG. A potentially deleterious effect of
certain anti-M protein IgG antibodies may also have implications
Figure 8. Lung pathology of mice injected with M1 protein and human serum. Balb/c mice were injected i.p. with serum from a non-
responder (3 mice, 1–3) or a responder (3 mice, 4–6), or with PBS (2 mice, 7–8). Twenty hours later the serum treated mice and one of the PBS treated
animals were injected i.v. with M1 protein, whereas the remaining mouse injected with PBS i.p. received PBS i.v. After another 4 hours the animals
were sacrificed and their lungs were analyzed by scanning electron microscopy. Panel A–C: lung tissue from the mice (1–3) treated with non-
responder serum plus M1 protein. Panel D–F: lung tissue from the mice (4–6) treated with responder serum and M1 protein. Panel G: lung tissue from
the mouse (7) that received PBS and M1 protein. Panel H; lung tissue from the mouse receiving buffer alone. Each lung tissue sample was evaluated
from 30 different fields covering an entire lung section and the percentage fields exhibiting hemorrhage and fibrin deposits is indicated for the 8
samples. Lung tissue samples from the animals that received responder serum and M1 protein (D–F), could be blindly distinguished from the other
samples.
doi:10.1371/journal.ppat.1000149.g008
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However, the development of such a vaccine has lately been
focused on epitopes either in the very NH2-terminal or in the
COOH-terminal regions of the protein, which do not include the
S domain (for references, see reviews [47,48]) . The present
investigation suggests that vaccines based on S domain-derived
peptides, represent a risk of inducing pro-inflammatory IgG
antibodies.
Sepsis in itself is a highly complex and multi-facetted syndrome
[49], and STSS is usually associated with both a severe focal
infection (for instance necrotizing fasciitis) and sepsis [4]. There is
no doubt there are many aspects of the molecular basis for STSS
pathogenesis that are still poorly understood, and the finding that a
protein released from the bacterial surface forms aggregates with
two human plasma proteins that activate neutrophils and induce a
powerful inflammatory response, further underlines the complex-
ity of the disease. However, a deeper molecular understanding of
the patho-physiology behind the vascular leakage, which is such a
pivotal symptom in STSS, should help optimize diagnosis and
therapy, and perhaps identify novel therapeutic targets.
Materials and Methods
Reagents
Recombinant M1 protein and fragments AS and SC3 of M1 as
well as IdeS and EndoS, were expressed in E. coli and purified as
previously described [18,19,21]. A synthetic peptide correspond-
ing to the S domain was produced by Biopeptide Co., Inc, San
Diego, CA. Recombinant M3 and M5 was produced as previously
described [50,51]. To avoid possible LPS effects in the animal
experiments, M1 protein was purified from the growth medium of
the isogenic mutant MC25 strain (derived from the AP1 strain;
40/58 S. pyogenes strain from the World Health Organization
Collaborating Centre for reference and Research on Streptococci,
Institute of Hygiene and Epidemiology, Prague, Czech Republic)
that lacks the membrane spanning region and secretes a soluble
form of the protein [52]. Briefly, the supernatant from a MC25
culture was collected, proteins were precipitated with ammonium
sulfate, dissolved in PBS, and purified on fibrinogen-coupled
Sepharose. The purity of the M1 protein preparation was
confirmed by SDS-PAGE analysis followed by Coomassie
staining.
Plasma absorption, IgG purification and IgG cleavage
Equal amounts of serum and protein G-Sepharose (Amersham)
were incubated for 2 hours in room temperature. The mixture was
centrifuged (2006g 1 min) and the supernatant collected. The
protein G-Sepharose was resuspended in PBS, transferred to a
column, washed thoroughly with PBS and then eluted with 0.1 M
glycine (pH 2.0). The eluate was buffered with 1 M Tris to pH 7.5
and the absorbance read at 280 nm. To certify that all IgG had
been absorbed from the supernatant, equal amounts of superna-
tant and protein G-Sepharose were again incubated and treated as
above. The eluate from this second step did not contain any
protein (no absorbance at 280 nm). IgG was purified by first
desalting serum using the Zeba
TM Desalt Spin Columns (Pierce)
Figure 9. Extensive formation of M1 protein-fibrinogen-IgG complexes is detected at the local site of S. pyogenes tissue infection. A
tissue biopsy obtained from a patient with necrotizing fasciitis and streptococcal toxic shock syndrome caused by an M1 strain, was sectioned, fixed,
and stained for the M1 protein, fibrinogen and IgG as detailed in Methods. The stainings were analyzed by confocal microscopy using a 636oil
objective lens. The figure shows simulated maximum projections of sequential scans at two different magnifications; panel A–D, scale bar=10 mm
and in panel E–H, scale bar=2 mm. A and E: M1 protein (Alexa 546, yellow), B and F: fibrinogen (Alexa 633, magenta), C and G: IgG (Alexa 488, green),
D and H: overlay. Despite a high degree of co-localization, each marker could be identified also individually (indicated by white squares in D). The area
indicated by the white rectangle in D was chosen for re-analysis at a higher magnification, panel E–H. The arrows in H indicate areas of co-localized
M1 protein, fibrinogen and IgG. Cellular infiltrates are shown in blue by the nuclear staining, dapi.
doi:10.1371/journal.ppat.1000149.g009
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TM Gel IgG Spin Purification Kit
(Pierce), as described by the manufacturer. To cleave IgG, 80 mg
(2 mg/ml) of IdeS or 20 mg (1.38 mg/ml) of EndoS was added to
200 ml of serum and the solutions were incubated in 37uC for
2 hours or overnight respectively. As a control, serum without
addition was treated likewise.
Preformed protein complexes
To 50 ml of plasma was added 0.5 mg of M1 protein. The
solution was left for 20 min at room temperature after which
40 mg of IdeS, 5 mg of EndoS, or buffer was added followed by
incubation for 2 hours in 37uC.
Neutrophil isolation
Human neutrophils were isolated from fresh human heparin-
ized blood from healthy volunteers using PolymorphprepH
(Fresenius Kabi) according to the manufacturer. When indicated,
the neutrophils were first washed at low speed (160g) prior to the
Polymorphprep step. Such preparations contained less than 10%
platelets (free or bound to neutrophils as determined by FACS).
Flow cytometry of neutrophil preparations
To 50 ml of isolated neutrophils were added 5 ml respectively of
flourochrome-conjugated antibody CD42PerCP (BD Bioscience)
and CD45FITC (Dakocytomation). After 10 minutes in room
temperature the incubation was stopped by addition of 0.5%
formaldehyde in PBS. Samples were analyzed using a FACSCa-
libur flow cytometer in linear as well as logarithmic mode. The
neutrophil population was identified by its characteristics in size
and granularity. Acquired cells were analyzed using Cell Quest
software (Becton Dickinson)
Determination of HBP
Neutrophils, suspended in Dulbecco’s PBS, or 50 ml human
blood (heparinized), diluted 10 times in Dulbecco’s PBS, were
incubated with various neutrophil-activating reagents for 30 min
at 37uC. In the experiments with supplemented serum or IgG,
serum (25 ml) or IgG (250 mg) from a responder or a non-
responder was added. IgG was, when indicated, pre-treated with
0.2 mg IdeS/mg IgG (IdeS 2 mg/ml) for 2 hours in 37uC. As a
control IgG without IdeS addition was treated likewise. Cells were
then centrifuged 120006g for 20 s and the resulting supernatants
were analyzed for HBP by sandwich ELISA [53]. In order to
establish the total amount HBP present, cells were lysed with
0.02% (v/v) Triton X-100 and pelleted as above.
Blocking experiments
To 500 ml of whole blood (diluted 1:10) 1 ml 10.1 (1 mg/ml)
(SerotecH)(anti-FccRI; CD64), 1 ml AT10 (1 mg/ml) (Serote-
cH)(anti-FccRII; CD 32), 1 ml LNK16 (1 mg/ml) (SerotecH)(anti-
FccRIII; CD 16) or 1 ml of an isotype control antibody (1 mg/ml)
(EbioscienceH) were added and incubated at 37uC for 20 minutes,
before the samples were subjected to M1 protein stimulation. The
antibodies are reported by the manufacturer to block the binding
of IgG to the concomitant Fcc-receptor and this has been
demonstrated by previous studies [54–56].
Determination of IgG antibodies against M1 protein
Anti-M1 IgG antibodies were detected using a modified
protocol from Holm et al [41]. Microtiter plates were pre-coated
with 200 ml of human fibrinogen (Sigma) (25 mg/ml) in coating
buffer (15.9 mM Na2CO3 and 35 mM NaHCO3 pH 9.6) over
night. The plates were then coated with 1.25 mg/ml M1 protein in
PBST (PBS, pH 7.4; 0.05% (v/v) Tween-20) for 1 hour at 37uC,
and then blocked using incubation buffer (PBST and 2% (w/v)
BSA) for 20 min at 37uC. Sera diluted 1:500 in incubation buffer
were added and incubated for 1 hour, 37uC. The plates were
rinsed and 200 ml of HRP-conjugated protein G (BioRad) (diluted
1:3000) added and incubated for 1 hour at 37uC. Each incubation
step was followed by a washing step. The plates were developed
using chromogenic substrate as described by Tapper et al. [53].
Octagam (human IgG 50 mg/ml) (Octapharma) was used as a
standard and the absorbance for each sera was expressed as an
ELISA-index in percent relative to the absorbance of Octagam.
For anti-M1 IgG antibodies in mice, sera were diluted 1:100 and
detection was made with 200 ml of HRP-conjugated goat anti-
mouse IgG (BioRad) (diluted 1:3000).
Bactericidal assay
The bactericidal test according to Lancefield [22] was
performed with the S. pyogenes strain AP1 in whole blood from
different donors.
Formation of protein aggregates in plasma by the
addition M1 protein
M1 protein (10 mg/ml [200 nM]) was added to 500 mlo f
plasma (diluted 1:10). The solution was left for 30 min at room
temperature and then centrifuged 120006g 1 min. The superna-
tant was removed and the protein aggregates in the pellet were
washed three times and then resuspended in sample buffer and
analyzed.
SDS-polyacrylamide gel electrophoresis and Western
blotting
Proteins were separated by 10% (w/v) SDS-PAGE in the
presence of 1% (w/v) SDS [57]. Proteins were transferred onto
polyvinyl chloride membranes for 60 min at 70 V. The mem-
branes were blocked with PBS containing 5% (w/v) dry milk
powder. Membranes were probed with polyclonal goat antibodies
against human IgG (H+L) conjugated with alkaline phosphatase
(Pierce) (dilution 1:5000) and color was developed using Nitro Blue
tetrazolium and 5-bromo-chloro-indoyl phosphate. To detect the
presence of complement in the aggregates the membranes were
probed with polyclonal goat IgG against complement C3 (1:500)
(purified with Protein G–Sepharose from polyclonal goat serum
against complement C3 (Sigma)). The binding was visualized with
rabbit anti-goat IgG conjugated to horse-radish peroxidase
(Dakocytomation) (1:1000) and developed by SuperSignal West
Pico Chemiluminescent substrate (Pierce) and visualized in a
ChemiDoc (BioRad). The same membrane was also probed with
polyclonal rabbit antibodies against human IgG conjugated with
horse-radish peroxidase (Dakocytomation) (1:2000) and the
membranes were developed using SuperSignal West Pico
Chemiluminescent substrate (Pierce) and visualized in a Chemi-
Doc (BioRad).
Surface plasmon resonance spectroscopy
Fibrinogen was diluted with 10 mM sodium acetate (pH 4.0)
and immobilized via amine coupling in a flow cell of a CM5 sensor
chip (BIAcore, Uppsala, Sweden). Immobilization level was
around 1500 resonance units. A flow cell subjected to the coupling
reaction without added protein was used as a control for bulk
refraction index changes. Binding and dissociation were monitored
in a BIAcore 2000 instrument. In control experiments for possible
mass transfer effects, M1 protein was injected over the fibrinogen
surface at different flow rates. No differences in initial binding rate
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limitations. The M1 protein was injected at a determined
concentration (500 nM) over the coated surface at 35 ml/min
and 25uC (in running buffer: 10 mM Hepes, pH 7.5, 150 mM
NaCl, 0.005% surfactant P20, and 3.4 mM EDTA). In sequence,
the different antibodies were injected at an apparent M1 protein
steady state binding resonance level. Antibodies were also injected
directly onto the fibrinogen surface as a built-in control. The
fibrinogen and blank surfaces were at the end of each experiment
regenerated. This was achieved by injection of a 200 ml 2 minute-
pulse of running buffer containing 2 M NaCl, followed by an
extensive wash procedure.
After X and Y normalization of data, the curves from the
control cell (blank) and the fibrinogen-antibody control were
subtracted. The curve forms of the different antibodies were
displayed in parallel using the BIA Evaluation 3.1 software
(BIAcore).
Transmission electron microscopy
M1 protein (27 mg/ml) was suspended in TBS buffer (20 mM
Tris, 150 mM NaCl pH 7.4). IgG was purified as described above
and applied to Zeba Desalting Spin Columns and buffered
exchanged with TBS as described by the manufacturer. Five mlo f
M1 protein were mixed with 5 ml IgG (0.8 mg/ml) in TBS buffer
and were left for 60 min in room temperature. IgG from a non-
responder and a responder were used separately. The mixtures
were diluted 1000 times in TBS and were analyzed by negative
staining and electron microscopy as described previously [58]. 5 ml
aliquots were adsorbed onto carbon-coated grids for 1 min,
washed with two drops of water, and stained on two drops of
0.75% uranyl formate. The grids were rendered hydrophilic by
glow discharge at low pressure in air. Specimens were observed in
a Jeol JEM 1230 electron microscope operated at 60 kV
accelerating voltage. Images were recorded with a Gatan Multi-
scan 791 CCD camera.
Scanning electron microscopy
Fifty ml human blood (heparinized) was diluted in Dulbecco’s PBS
to a final volume of 500 ml, and incubated with buffer or M1 protein
(1 mg/ml) for 30 min at 37uC. One hundred ml of the solution were
taken off and fixed in 9.25% formaldehyde and 3.25% methanol in
PBS. After 60 s of fixation 4 ml of Tyrode’s buffer (137 mM NaCl,
2.8 mM KCl, 1 mMMgCl2,1 2mMNa HC O 3,0 . 4m MNa 2HPO4,
0.35% BSA, 10 mM HEPES and 5.5 mM Dextrose; pH 7.4) were
added and left for 30 min lysing the erythrocytes. After washing in
Tyrode’s buffer twice, 25 ml of the lysate was applied to poly-L-lysine
coated cover slips for 1 h, and subsequently fixed in 2.5%
glutaraldehyde in 0.15 M sodium cacodylate, pH 7.4, (cacodylate
buffer) for 30 min at room temperature. Specimens were washed
with cacodylate buffer, and dehydrated with an ascending ethanol
series from 50% (v/v) to absolute ethanol (10 min per step). The
specimens were then subjected to critical-point drying in carbon
dioxide, with absolute ethanol as intermediate solvent, mounted on
aluminium holders, sputtered with 30 nm palladium/gold, and
examined in a JEOL JSM-350 scanning electron microscope. The
remaining 400 ml of the blood-M1 protein solution was analyzed for
HBP as described above.
Animal experiments
Male BALB/c mice (11 weeks old) were housed under standard
conditions of light and temperature and fed with standard
laboratory chow and water ad libitum. All animal experiments
were approved by the ethics committee at Lund University.
Animals were given an intraperitoneal injection of 0.3 ml of serum
or PBS. After 20 hours the animals were anaesthetized with
isoflurane and given an intravenous injection of 15 mg M1 per
animal or 100 ml vehicle alone. Four hours post administration of
M1 the mice were sacrificed. A blood sample was collected via
cardiac puncture and the lungs were removed. Lung samples were
fixed in 2.5% glutaraldehyde in 0.15 M sodium cacodylate,
pH 7.4, (cacodylate buffer) over night at room temperature.
Specimens were washed with cacodylate buffer, and dehydrated
with an ascending ethanol series from 50% (v/v) to absolute
ethanol (10 min per step). The specimens were then subjected to
critical-point drying in carbon dioxide, with absolute ethanol as
intermediate solvent, mounted on aluminium holders, sputtered
with 30 nm palladium/gold, and examined in a JEOL JSM-350
scanning electron microscope.
Immunofluorescence and confocal microscopy
A snap-frozen tissue biopsy collected from the epi-center of
infection (fascia) from a patient with necrotizing fasciitis and
streptococcal toxic shock syndrome caused by an M1T1 S. pyogenes
strain (kindly provided by Prof. Donald E Low, Mount Sinai
Hospital, Toronto, Canada) was cryosectioned, and the sections
fixed and immunostained as previously described [11,59]. All
antibodies and fluorochromes were diluted in PBS-saponin
supplemented with Aurion BSA-c. Staining for fibrinogen was
obtained by incubation overnight with purified rabbit anti-
fibrinogen antibodies (Dakocytomation) diluted to a concentration
of 3 mg/ml, followed bya 30 min incubationwith biotinylatedgoat-
anti-rabbit IgG (diluted 1:500; Vector Laboratories, Burlingame,
CA), and subsequent addition of streptavidin conjugated Alexa
Fluor 633 (diluted 1:500; Molecular Probes, Eugene, OR, USA).
The M1 protein staining was achieved by incubation overnight with
biotinylatedpurified polyclonal rabbitanti-M1 protein antibodies at
a concentration of 2 mg/ml, followed by streptavidin conjugated
Alexa Fluor 546 (diluted 1:500; Molecular Probes). Immunoglob-
ulins weredetected by incubation with protein L from theanaerobic
bacterial species Finegoldia magna, a protein with high affinity for Ig
light chains [29]. A biotinylated protein L was used at a
concentrationof0.5 mg/ml anddetected bystreptavidinconjugated
Alexa Fluor 488 (diluted 1:600; Molecular Probes). Vectashield
supplemented with dapi (Vector Lab.) was used as mounting media.
The co-localization of all three markers was assessed in a triple
staining. The staining pattern (i.e. area and intensity of positive
signals) for each marker was highly similar in single and triple
stainings. Hence, non-specific signals due to interactions between
antibodies or with the Fc-binding portions of the M-protein could
be excluded. Sections stained in an identical manner, except for
omission of primary antibody, were used to set the threshold of the
laser. This threshold level was then applied for the entire analysis;
thereby controlling for autofluorescence in the tissue. For
evaluation, the Leica confocal scanner TCS2 AOBS with an
inverted Leica DMIRE2 microscope was used.
Statistical methods
Differences between various treatments of blood samples were
assessed with respect to release of HBP first with ANOVA or
ANOVA on ranks, and if a difference was proven the different
groups were compared against the control sample with Dunnett’s
2 sided test or Mann Whitney U test. P-values of 0.05 or less were
regarded as significant.
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